Home » Topics » Infection, BioWorld Science

Infection, BioWorld Science
RSS

Innovation Pharmaceuticals receives pre-IND response for brilacidin trial in COVID-19

Nov. 4, 2020

Senhwa submits IND for phase II trial of silmitasertib for severe COVID-19

Nov. 3, 2020

FDA clears initiation of phase III trial of itolizumab in COVID-19 patients with ARDS

Nov. 3, 2020

Second-generation anti-HCV cyclophilin inhibitor with reduced immunosuppressive activity

Nov. 3, 2020

Enanta Pharmaceuticals divulges new antivirals

Nov. 3, 2020

FDA clears IND application for phase I study of CORVax12 vaccine candidate for COVID-19

Nov. 3, 2020

IDMC recommends modification of REGN-COV2 trial in hospitalized COVID-19 patients

Nov. 2, 2020

FDA approves IND for TaiGen's pan-influenza antiviral TG-1000

Nov. 2, 2020

Genentech's antibody-antibiotic conjugate compared to SOC antibiotics in S. aureus

Nov. 2, 2020

Clinical trial begins in Brazil with nasally administered foralumab for COVID-19

Nov. 2, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...